TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6885176
Drug: Erythromycin lactobionate
Normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin lactobionate (1 g in 0.9% NaCl) infused in 250 ml
Study: 6885176
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl) infused in 120 ml
Study: 6885176
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% NaCl) infused in 250 ml
Study: 30091666
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg/day) with resistance training
Study: 30091666
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg/day) without resistance training
Study: 22395762
Drug: Multicomponent psychological
Normalized name: meningococcus B, multicomponent vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent psychological intervention (milieu therapy interventions and music therapy) for 6 months
Study: 22395762
Drug: Standard occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard occupational therapy
Study: 9793313
Drug: Budesonide 0.8
Normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.8 mg/day
Study: 9793313
Drug: Budesonide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 1.2 mg/day
Study: 9793313
Drug: Budesonide 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 2.4 mg/day
Study: 9793313
Drug: Budesonide 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 3.2 mg/day
Study: 2777592
Drug: Betadine‐R solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betadine‐R solution
Study: 1206393
Drug: L-tryptophan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (1.5 g or 8 g daily for 30 days)
Study: 1206393
Drug: Placebo (30-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30-day period after treatment)
Study: 27890885
Drug: Administration Timing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration Timing Simplification Protocol (ATSP)
Study: 23263204
Drug: Inhalation anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthesia with fentanyl (Group I)
Study: 23263204
Drug: Inhalation anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthesia with remifentanil (Group II)
Study: 23263204
Drug: Intravenous anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anaesthesia (TIVA) with propofol and remifentanil (Group III)
Study: 19243712
Drug: Extended-release niacin/laropiprant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin/laropiprant (ERN/LRPT) combination
Study: 16677158
Drug: Pantoprazole infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole infusion (80 mg intravenous bolus followed by an infusion at a rate of 8 mg per hour for 72 hours)
Study: 16677158
Drug: Pantoprazole infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole infusion
Study: 10341332
Drug: HGV antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGV antibodies detection by serological assay
Study: 7574743
Drug: HAI chemotherapy
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI chemotherapy with 5-FU 500 mg/day for 6 weeks
Study: 7574743
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no regional chemotherapy)
Study: 1973865
Drug: Astemizole 10-mg
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 10-mg tablets
Study: 6157338
Drug: Antihistamine-decongestant combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine-decongestant combination (azatadine maleate and pseudoephedrine sulfate)
Study: 30685679
Drug: SurVeil drug-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: SurVeil drug-coated balloon (DCB)
Study: 30685679
Drug: IN.PACT Admiral
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN.PACT Admiral drug-coated balloon (DCB)
Study: 21399488
Drug: Epirubicin, cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin, cisplatin, and continuous infusion of 5‐fluorouracil (ECF)
Study: 17244772
Drug: Maribavir 400
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir 400 mg
Study: 15642685
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oral vitamin K
Study: 11997407
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects on HRV
Study: 7712526
Drug: Creatine phosphate
Normalized name: Creatine phosphate
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine phosphate (CP) 18 g administered intravenously for 3 days
Study: 2655543
Drug: Deflazacort (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort (18 + 18 mg)
Study: 2655543
Drug: Prednisone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (15 + 15 mg)
Study: 2655543
Drug: Betamethasone disodium
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone disodium phosphate (1.5 + 1.5 mg)
Study: 31493952
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion (1 mg lidocaine/kg bolus followed by 180 mg lidocaine/hour for 7 days)
Study: 7977713
Drug: ouabain (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ouabain (0.5 mg i.v. 42 and 18 h before study)
Study: 2732784
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg twice a day)
Study: 2732784
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) (160 mg trimethoprim and 800 mg sulfamethoxazole twice a day)
Study: 27566723
Drug: Brexpiprazole (3.6mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole (3.6mg mean dose at last visit)
Study: 23623280
Drug: CRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT plus cetuximab (400 mg/m² on day 1 followed by 250 mg/m² weekly)
Study: 23623280
Drug: CRT only
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT only (cisplatin 60 mg/m² on day 1 and capecitabine 625 mg/m² twice daily for four cycles)
Study: 18802999
Drug: Pyridostigmine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (30 mg/8 hp. o)
Study: 11912281
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg levonorgestrel (two doses of 0.375 mg each, 12 hours apart)
Study: 20833596
Drug: Healthy Girls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Girls Project intervention (4 weekly workshops with psychoeducational and behavioral components)
Study: 18801028
Drug: N-acetylcysteine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (1200 mg daily for 4 months)
Study: 9189040
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (i.v.Ig) 0.4 gm/kg daily for either 3 days (n = 23) or 5 days (n = 23)
Study: 9189040
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (i.v.Ig)
Study: 4022702
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (limited starvation, group B)
Study: 24782199
Drug: Ondansetron 32
Normalized name: ondansetron 32 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 32 mg IV
Study: 24782199
Drug: Ondansetron 16
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 16 mg IV
Study: 20039806
Drug: DeltaNS1‐H1N1 A/New
Approvals — FDA: no, EMA: no, PMDA: no
Description: DeltaNS1‐H1N1 A/New Caledonia vaccine at 1 of 5 dose levels (6.4, 6.7, 7.0, 7.4, and 7.7 log(10) median tissue culture infective dose)
Study: 20039806
Drug: DeltaNS1‐H1N1 A/New
Approvals — FDA: no, EMA: no, PMDA: no
Description: DeltaNS1‐H1N1 A/New Caledonia vaccine
Study: 15916468
Drug: Betaine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (6 g/d for 6 weeks)
Study: 15916468
Drug: Phosphatidylcholine (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylcholine (approximately 2.6 g/d of choline for 2 weeks)
Study: 15916468
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg/d)
Study: 10553160
Drug: Fludarabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine alone (25 mg/m²/day for 5 days)
Study: 10553160
Drug: Fludarabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine and idarubicin (FLU-ID: fludarabine 25 mg/m² i.v. on days 1 to 3 and idarubicin 12 mg/m² i.v. on day 1)
Study: 6368889
Drug: Rifampin-20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin-20 (20 mg/kg/dose for four days)
Study: 6368889
Drug: Rifampin-10 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin-10 (10 mg/kg/dose for two to four days)
Study: 29517695
Drug: Group S
Normalized name: Blood group substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S (n=27; dose reduced by 10% of each ED95)
Study: 29517695
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (n=27; dose reduced by 20% of each ED95)
Study: 26581819
Drug: Extended medication
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended medication (26 weeks of nicotine patch + nicotine gum)
Study: 26581819
Drug: Extended medication
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended medication (8 weeks of nicotine patch + nicotine gum)
Study: 26581819
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence counseling
Study: 26581819
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication adherence counseling
Study: 26581819
Drug: Automated (medication)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated (medication) adherence calls
Study: 26581819
Drug: Electronic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic medication monitoring with feedback and counseling
Study: 26581819
Drug: Electronic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic medication monitoring alone
Study: 23787544
Drug: Paricalcitol 1
Normalized name: PARICALCITOL 1MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol 1 μg/day
Study: 21558570
Drug: Quercetin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin supplementation (500 mg of quercetin-3-glucoside, consumed twice a day, totaling 1,000 mg/d)
Study: 19433274
Drug: Clonidine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.05 mg, twice daily)
Study: 19433274
Drug: Levetiracetam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (10 mg/kg/day, divided twice daily)
Study: 27029450
Drug: Noophen 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noophen 500 mg/day
Study: 24493231
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and metronidazole (AB) for 7 days
Study: 24493231
Drug: Antibacterial photodynamic
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial photodynamic therapy (aPDT) with two episodes
Study: 22331154
Drug: Conventional supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional supervised toothbrushing program (oral health education and dental plaque dying followed by toothbrushing with fluoride dentifrice four times per year)
Study: 21384736
Drug: Local corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid injection plus splinting
Study: 21178933
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg.kg-1 bm)
Study: 9610454
Drug: Systemic diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic diclofenac sodium 50 mg given orally 1 hour before surgery
Study: 7804666
Drug: Tiapride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (100 mg three times a day for at least one month)
Study: 3243926
Drug: Intravenous ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ranitidine (50 mg over 5 minutes)
Study: 11396641
Drug: Innovative techniques
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovative techniques and promising new drugs for the treatment of advanced epithelial ovarian cancer
Study: 24829038
Drug: Specialized multidisciplinary
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized multidisciplinary tinnitus treatment based on cognitive behavioral therapy
Study: 23242019
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg intravenously twice a day for fasting time, then 40 mg orally twice a day until discharge
Study: 20152243
Drug: Ezetimibe/simvastatin (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin (10/20 mg) plus niacin (to 2 g)
Study: 20152243
Drug: Ezetimibe/simvastatin (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin (10/20 mg)
Study: 18817156
Drug: Combined sciatic-femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sciatic-femoral nerve block with ropivacaine 25 mL 0.75 mg
Study: 2279254
Drug: Ibopamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (100 mg t.i.d.) for 3 weeks
Study: 2279254
Drug: Ibopamine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (300 mg daily for 3 weeks)
Study: 41542
Drug: Quinalbarbitone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinalbarbitone 200 mg
Study: 41542
Drug: Quinalbarbitone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinalbarbitone 100 mg
Study: 30646926
Drug: LOWFODMAP diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOWFODMAP diet (16.06 ± 1.79 g·d‐ 1)
Study: 30646926
Drug: HIGHFODMAP diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGHFODMAP diet (38.65 ± 6.66 g·d‐ 1)
Study: 27230850
Drug: LCZ696 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with mild renal impairment (N=8)
Study: 27230850
Drug: LCZ696 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with moderate renal impairment (N=8)
Study: 27230850
Drug: LCZ696 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 400 mg once daily (QD) on days 1 and 5 in patients with severe renal impairment (N=6)
Study: 27230850
Drug: Healthy subjects
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects (CrCl >80 mL/min)
Study: 21935705
Drug: Vorapaxar 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar 20 mg
Study: 21935705
Drug: Vorapaxar 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar 40 mg
Study: 21935705
Drug: Vorapaxar 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar 5 mg/day
Study: 21935705
Drug: Vorapaxar 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar 1 mg/day
Study: 21935705
Drug: Vorapaxar 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar 3 mg/day
Study: 21122285
Drug: Therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with ESWT (shock waves) and proprioceptive Multi Joint System, along with a specific nutritional supplement.
Study: 21122285
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement in Group B2.
Study: 21122285
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group B1 without nutritional supplement).
Study: 11232674
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once a day in the evening
Study: 11232674
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg once a day in the morning
Study: 9923581
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg orally once daily for 5 days
Study: 21410371
Drug: Intermediate-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose cytarabine (200 mg/m² continuous IV infusion for 24 hours in cycle 1 and 1000 mg/m² by infusion for 3 hours twice daily in cycle 2)
Study: 21410371
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (1000 mg/m² every 12 hours in cycle 1 and 2000 mg/m² twice daily in cycle 2)
Study: 17166332
Drug: α1-adrenergic receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: α1-adrenergic receptor antagonists (α1-AR)
Study: 17166332
Drug: Phosphodiesterase type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase type 5 inhibitors (PDE-5s)
Study: 17166332
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of α1-AR antagonist and PDE-5
Study: 15909750
Drug: Ethambutol therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethambutol therapy
Study: 9196083
Drug: rhuMAb-E25 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuMAb-E25 (2 mg/kg on Day 0 and 1 mg/kg on Days 7, 14, 28, 42, 56, and 70)
Study: 8308939
Drug: Traditional alcoholism
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional alcoholism treatment for alcohol and cocaine abusers
Study: 8308939
Drug: Traditional alcoholism
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional alcoholism treatment for alcohol-only patients
Study: 3083718
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg nicardipine
Study: 3083718
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg nicardipine
Study: 17701271
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (10,000 lux, n = 10)
Study: 15860501
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (ganirelix) administered daily from the 8th day of stimulation
Study: 15860501
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (triptorelin) long protocol
Study: 12595851
Drug: Dobutamine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (mean dose 4.1 +/- 1.4 microg/kg/min)
Study: 12595851
Drug: Milrinone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (mean dose 0.39 +/- 1.0 microg/kg/min)
Study: 10528419
Drug: Acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 300 mg per day for 24 weeks
Study: 7084138
Drug: Oral information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral information about medications at initial interview
Study: 3971235
Drug: Antiphlebitic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiphlebitic mixture of heparin‐hydrocortisone‐sodium bicarbonate
Study: 24762026
Drug: Multifactorial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multifactorial intervention including motivational aspects, cognitive aspects, and training in inhalation techniques
Study: 26252875
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily for 24 weeks
Study: 26252875
Drug: Telaprevir 750
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir 750 mg three times daily for 12 weeks and peginterferon/ribavirin for 24 weeks
Study: 20817281
Drug: Double-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose clopidogrel (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily)
Study: 20817281
Drug: Standard-dose clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose clopidogrel (300 mg on day 1 then 75 mg daily)
Study: 20817281
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (300-325 mg daily)
Study: 20817281
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (75-100 mg daily)
Study: 18623043
Drug: Clindamycin 600
Normalized name: clindamycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin 600 mg oral dose
Study: 2616352
Drug: Sucralfate pretreatment
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate pretreatment (1-g dose at 6 and 2 hours before ciprofloxacin)
Study: 29752024
Drug: Vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine plus behavioral change
Study: 10063787
Drug: bisoprolol/6.25‐mg hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol/6.25‐mg hydrochlorothiazide (HCTZ)
Study: 2124033
Drug: Valproate (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (1000 mg/day)
Study: 2124033
Drug: Taltrimide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taltrimide (400 mg/day)
Study: 19180516
Drug: Pamapimod 50
Normalized name: Pamapimod
DrugBank: Pamapimod (DB19169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamapimod 50 mg